MOTS-c
Also known as: Mitochondrial open reading frame of the 12S rRNA type-c, Mitochondrial ORF of the twelve S-c, MOTS-c peptide, Mitochondrial-derived peptide MOTS-c, Mitokine MOTS-c, 12S rRNA-c peptide
Mitochondrial-derived peptide (MDP) / Mitokine — 16-amino-acid peptide encoded within the 12S rRNA short open reading frame of the mitochondrial genome
What it is
MOTS-c is a peptide naturally produced by mitochondria during exercise and metabolic stress, studied for insulin resistance, obesity, aging, and cardiovascular protection. It works by activating pathways inside cells that improve how the body handles glucose and fat. Not FDA-approved; classified as a gray-market research compound; preclinical data is promising.
The scientific side
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame (sORF) within the 12S rRNA gene of the mitochondrial genome. Under metabolic stress (e.g., glucose restriction, oxidative stress, exercise), MOTS-c translocates from mitochondria to the nucleus, where it regulates nuclear gene expression—including genes bearing antioxidant response elements (ARE)—and interacts with stress-responsive transcription factors such as NRF2/NFE2L2. Its primary described cellular mechanism involves inhibition of the folate cycle and de novo purine biosynthesis, leading to AMPK activation. MOTS-c activates AMPK, which in turn regulates downstream effectors including PGC-1α, HIF-1α, mTORC1, and PFKFB3, thereby modulating energy metabolism, mitochondrial biogenesis, glycolysis, oxidative stress responses, inflammation, autophagy, and apoptosis. MOTS-c also functions as a host defense peptide with direct antibacterial activity against pathogens including E. coli and MRSA, targeting bacterial membranes via its hydrophobic and cationic domains, and modulates innate immune cell differentiation. MOTS-c facilitates plasma membrane repair via interaction with TRIM72 and plasma lipids, interacts directly with intracellular proteins including Bcl-2, MYH9/actin complexes and LARS1, and acts on the KEAP1-NRF2 pathway. Circulating MOTS-c is detected in plasma; levels decline with age and are reduced in numerous disease states.
Class: Mitochondrial-derived peptide (MDP) / Mitokine — 16-amino-acid peptide encoded within the 12S rRNA short open reading frame of the mitochondrial genome
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. One narrative review classifies MOTS-c among 'unapproved peptides' operating in a 'gray market' outside regulatory oversight, but does not state specific…
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Metabolic homeostasis, insulin resistance, and obesity Mixed
- MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity; primary target organ is skeletal muscle; acts via folate-AICAR-AMPK pathway. PMID 25738459 Lee et al., Cell Metabolism 2015
- MOTS-c prevented ovariectomy-induced obesity and insulin resistance in mice; activated AMPK pathway to improve energy dissipation and insulin sensitivity. PMID 30725119 Lu et al., J Mol Med 2019
- MOTS-c increased mitofusion (OPA1, MFN2) and GLUT4 translocation in mammalian cells; MFN2 knockdown abrogated GLUT4 translocation. PMID 34253808 Bhullar et al., Sci Rep 2021
- In 85 human subjects, serum MOTS-c levels were not significantly different between obese and normal-weight individuals; age and HOMA-IR were significant determinants of MOTS-c levels. PMID 41004666 Yildiz Ozkaya et al., Arch Endocrinol Metab 2025
- Type 2 diabetes mellitus and diabetic complications Mixed
- Review summarising MOTS-c associations with T2DM risk factors and diabetic cardiomyopathy; compiles preclinical exogenous MOTS-c dosing schedules. PMID 41083123 Fang et al., Life Sci 2025
- Review of MOTS-c research in type 1 and type 2 diabetes, highlighting regulatory roles in cellular metabolism and insulin action. PMID 36824008 Kong et al., Diabetes Metab J 2023
- Type 1 diabetes / autoimmune pancreatic islet protection Animal studies only
- MOTS-c prevented autoimmune β-cell destruction in NOD mice by modulating T cell phenotype via TCR/mTORC1 signaling; T1D patients had lower serum MOTS-c than healthy controls. PMID 34320351 Kong et al., Cell Reports 2021
- Aging and physical performance / healthspan Mixed
- MOTS-c enhanced physical performance in young, middle-age, and old mice; late-life intermittent MOTS-c treatment (3x/week) increased physical capacity and healthspan; exercise induces endogenous MOTS-c expression in human skeletal muscle and circulation. PMID 33473109 Reynolds et al., Nat Commun 2021
- Review: plasma MOTS-c levels decline with age; MOTS-c has beneficial effects in age-related diseases including diabetes, cardiovascular disease, osteoporosis, postmenopausal obesity, and Alzheimer's. PMID 36761202 Zheng et al., Front Endocrinol 2023
- Review: MOTS-c levels decline with age; aging characterized by gradual loss of mitochondrial metabolic balance potentially reversible with MOTS-c treatment. PMID 36233287 Mohtashami et al., IJMS 2022
- Skeletal muscle homeostasis, performance, and cachexia Mixed
- MOTS-c augmented muscle mitochondrial bioenergetic performance via PGC-1α and AMPK in transgenic mice; lowered mitochondrial ROS emission and oxidative stress; no change in arterio-venous MOTS-c difference during exercise in humans. PMID 41520850 Gudiksen et al., Free Radic Biol Med 2026
- Serum MOTS-c levels closely associated with aerobic exercise capacity in marathon runners; endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion and activating AMPK/PGC-1α. PMID 39706498 Feng et al., Free Radic Biol Med 2025
- In physically active humans, serum MOTS-c positively correlated with average power, force, overall muscle mass, and leg muscle mass; no correlation with peak VO2. PMID 37834399 Domin et al., IJMS 2023
- MOTS-c (15 mg/kg/2x day i.p.) partially preserved skeletal muscle mass in C26 tumor-bearing mice; attenuated cachexia-induced upregulation of Atrogin-1 and MuRF1; increased PGC-1α and AMPK phosphorylation in vitro. PMID 42266945 Jamnick et al., Front Med 2026
- Wild-type MOTS-c increased myotube formation in human and murine muscle progenitor cells in vitro; blocked IL-6-induced STAT3 transcriptional activity via putative SH2 binding motif in the YIFY region. PMID 35842023 Garcia-Benlloch et al., Peptides 2022
- Cardiovascular disease (coronary artery disease, myocardial infarction, heart failure) Mixed
- Lower circulating MOTS-c associated with impaired coronary endothelial function in humans; MOTS-c (2 µg/ml) improved vascular responsiveness to acetylcholine in rat and RAS-mouse aortic rings ex vivo. PMID 29242099 Qin et al., Int J Cardiol 2018
- MOTS-c levels lower in stable CAD patients vs. controls (111±13 vs. 161±23); MOTS-c ≥130.9 had 80.3% sensitivity and 73.2% specificity for predicting CAD. PMID 36066139 Yasar et al., Eur Rev Med Pharmacol Sci 2022
- MOTS-c levels significantly lower in STEMI group vs. controls; MOTS-c ≥84.15 pg/mL predicted no-reflow with 95.3% sensitivity and 88.9% specificity (AUC 0.95); strong independent predictor of in-hospital MACE. PMID 36629605 Cakmak et al., Arq Bras Cardiol 2023
- MOTS-c deficiency persisted during cardiac de-acclimatization after high-altitude exposure in mice; exogenous MOTS-c activated PINK1/Parkin pathway, promoted mitophagy, and alleviated cardiac dysfunction; reduced circulating MOTS-c observed in patients with high-altitude heart disease and acute coronary syndrome. PMID 41654147 Feng et al., Free Radic Biol Med 2026
- Plasma MOTS-c decreased in AF patients and inversely correlated with NT-proBNP; MOTS-c treatment reduced AF inducibility and attenuated atrial fibrosis and mitochondrial fission in mouse models. PMID 42193373 Liao et al., Biomedicines 2026
- Lung injury and respiratory diseases Mixed
- Review: circulating MOTS-c levels reduced in acute respiratory distress; exogenous MOTS-c attenuates lung injury in preclinical models; MOTS-c decreased in COPD, OSA, and asthma; potentially increased in lung cancer. PMID 42243958 Amado et al., J Transl Med 2026
- MOTS-c mediates RIPC-induced protection against lung ischemia-reperfusion injury via Nrf2 pathway in mice; serum MOTS-c decreased post-IR injury but increased with RIPC prior to lung transplantation. PMID 39827923 Wang et al., Free Radic Biol Med 2025
- MOTS-c serum increments post-CPB (ΔMOTS-c) predicted ARDS with AUC 0.885; exogenous MOTS-c attenuated lung injury via ROS-CK2A-MYH9 signaling and antioxidant gene transcription in rats. PMID 40403491 Shen et al., Redox Biol 2025
- MOTS-c plasma concentrations reduced in CPB patients with ALI; MOTS-c pretreatment alleviated LIRI via AMPK-HIF-1α-PFKFB3 glycolytic pathway in mice and cell models. PMID 40035775 Shen et al., Am J Respir Cell Mol Biol 2025
- Circulating MOTS-c decreased in postoperative ALI patients; MOTS-c suppressed ferroptosis and alleviated MIR-induced ALI via PPARγ signaling in rats and MLE-12 cells. PMID 37290680 Lu et al., Eur J Pharmacol 2023
- Engineered R13A-MOTS-c (5 mg/kg/day i.p. for 2 weeks) mitigated radiation-induced pulmonary inflammation and mitochondrial dysfunction via LAT1-mediated transport and Nrf2 activation in C57BL/6 mice. PMID 42142418 Zhang et al., Redox Biol 2026
- MOTS-c content reduced in hyperoxia-induced BPD mice; exogenous MOTS-c alleviated alveolar simplification and pulmonary vascular abnormalities in Nrf2-dependent manner. PMID 41802484 Chen et al., Eur J Pharmacol 2026
- MOTS-c levels lower in asthma patients vs. healthy volunteers; MOTS-c alleviated allergic asthma airway barrier dysfunction via Nrf2-dependent inhibition of epithelial apoptosis in HDM-stimulated mice and BEAS-2B cells. PMID 40472776 Zhang et al., Int Immunopharmacol 2025
- Non-alcoholic steatohepatitis (NASH) and liver injury Animal studies only
- MOTS-c alleviated NASH-diet-induced liver steatosis, apoptosis, inflammation, and fibrosis in mice; interacts directly with BH3 domain of Bcl-2, increasing Bcl-2 stability. PMID 38206815 Lu et al., Cell Reports 2024
- MOTS-c reduced APAP-induced liver injury in C57BL/6 mice via suppression of MAPK pathway (ERK, JNK, p38), reduced oxidative stress, inflammation, and apoptosis; MOTS-c levels reduced in AILI mice. PMID 41764620 Li et al., Protein Peptide Lett 2026
- Cancer (ovarian cancer, hepatocellular carcinoma, bone cancer pain, adrenal tumors) Mixed
- MOTS-c levels reduced in serum and tumor tissues of ovarian cancer patients; exogenous MOTS-c inhibited OC cell proliferation, migration, invasion, and induced apoptosis in vitro and suppressed tumor growth in vivo via LARS1-USP7 ubiquitination axis. PMID 39321430 Yin et al., Adv Sci 2024
- MOTS-c levels lower in HCC patient peripheral blood; MOTS-c promoted TRAIL-induced HCC cell apoptosis under hypoxia via MEF2A/DR4/DR5 axis. PMID 39581216 Shen et al., Exp Cell Res 2025
- Endogenous MOTS-c lower in bone cancer pain mouse model; intraperitoneal MOTS-c robustly attenuated bone cancer-induced pain and bone destruction via AMPK-mediated mitochondrial biogenesis; chronic administration had little effect on liver, renal, lipid, or cardiac function in mice. PMID 38716540 Yang et al., Acta Biochim Biophys Sin 2024
- MOTS-c mRNA decreased in all adrenal tumors vs. controls; serum MOTS-c protein increased in ACA and PCC but not ACC; MOTS-c protein expression declined with ACC stage progression. PMID 39201408 Kaminski et al., IJMS 2024
- Osteoporosis and bone metabolism In vitro only
- MOTS-c (1.0 µM for 24 h or 0.5 µM for 48 h) increased osteoblast viability and promoted type I collagen synthesis (COL1A1, COL1A2) via TGF-β/SMAD signaling in hFOB1.19 cells. PMID 31081069 Che et al., Eur Rev Med Pharmacol Sci 2019
- Osteoarthritis and cartilage protection Animal studies only
- Exogenous MOTS-c improved mitochondrial dysfunction, inhibited NLRP3 inflammasome, rescued chondrocyte pyroptosis, and delayed articular cartilage degeneration in a murine OA model via Nrf2/TXNIP/NLRP3 axis. PMID 41043625 Li et al., Free Radic Biol Med 2025
- Ischemic flap / soft tissue transplantation survival Animal studies only
- MOTS-c improved blood perfusion, enhanced angiogenesis, reduced endothelial pyroptosis, enhanced autophagy, and attenuated lysosomal membrane permeabilization in ischemic flap mice via PLA2G4A-LMP axis. PMID 42153537 Shi et al., Autophagy 2026
- Intrauterine growth restriction (IUGR) / placental protection Animal studies only
- MOTS-c (5 mg/kg) significantly attenuated hypoxia-induced IUGR by promoting placental angiogenesis and inhibiting oxidative stress in an Nrf2-dependent manner in mice. PMID 41268602 Chen et al., Int J Mol Med 2026
- Host defense / antibacterial activity Mixed
- MOTS-c identified as a mitochondrial-encoded host defense peptide; targeted E. coli and MRSA membranes; fully neutralized MRSA infectivity in mouse acute peritonitis model; IFNγ and LPS induced endogenous MOTS-c expression in human monocytes; MOTS-c reprogrammed monocytes into macrophages with enhanced bacterial cleara PMID 42611943 Rice et al., eLife 2026
- Antiviral activity (hepatitis B virus infection) Mixed
- MOTS-c negatively correlated with HBV DNA (R=-0.71); AUC 0.9530 for distinguishing CHB from healthy controls; 50-70% inhibition rate of HBV replication in vitro and in vivo; promotes mitochondrial biogenesis and MAVS signaling; no notable toxicity reported. PMID 37788894 Lin et al., Gut 2024
- Neurodegenerative diseases and ischemic stroke Human observational
- Plasma MOTS-c decreased in Alzheimer's disease and acute ischemic stroke groups vs. controls; similar values in MS group vs. control. PMID 36303331 Sacmaci et al., J Biochem Mol Toxicol 2023
- Sarcopenia in peritoneal dialysis patients Human observational
- PD patients with very high sarcopenia risk (SARC-F ≥2) had significantly lower serum MOTS-c and higher dialysate MOTS-c; serum MOTS-c directly correlated with muscle performance; ROC analysis supported diagnostic potential of MOTS-c for sarcopenia risk in PD patients. PMID 40005438 Zicarelli et al., Medicina 2025
- Pulmonary fibrosis Animal studies only
- Review suggesting MOTS-c potential in pulmonary fibrosis based on its effects on glucose/lipid metabolism, mitochondrial homeostasis, and anti-inflammatory properties; no direct PF trial data presented. PMID 37307934 Zhang et al., Mitochondrion 2023
- Mesenchymal stem cell aging (in vitro) In vitro only
- MOTS-c promoted homeostasis in aged human placenta-derived MSCs; activated AMPK, inhibited mTORC1, decreased ROS production and lipid synthesis in vitro. PMID 33639272 Yu et al., Mitochondrion 2021
- Skeletal muscle fiber composition and genetic variation (K14Q polymorphism) Human observational
- East Asian-specific m.1382A>C polymorphism (K14Q) associated with higher MHC-IIx (fast-twitch fiber) proportion, higher peak torques of leg flexion/extension in men, and higher C allele frequency in sprint/power athletes vs. endurance athletes. PMID 34728329 Kumagai et al., BBA Gen Subj 2022
Protocol
5 mg subcutaneous injection, 3x per week. Cycle: 4-8 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not stated in abstract | Not explicitly stated in abstract; described as preventing age-dependent and high-fat-diet-induced insulin resistance and obesity in mice | Not stated in abstract | animal | Research PMID 25738459 |
| Not stated in abstract | Intermittent MOTS-c treatment 3x/week (dose amount not stated in abstract) | Late-life initiated (23.5 mo. mice); duration not further specified in abstract | animal | Research PMID 33473109 |
| Not explicitly stated in abstract | 5 mg/kg | Gestational days 11–17.5 (hypoxia exposure period) | animal | Research PMID 41268602 |
| Intraperitoneal | 5 mg/kg/day (R13A-MOTS-c, an engineered variant) | 2 weeks | animal | Research PMID 42142418 |
| Intraperitoneal | Intraperitoneal administration; dose amount not stated in abstract | Chronic administration; duration not stated in abstract | animal | Research PMID 38716540 |
| Intravenous (in mice) | Not stated in abstract | Not stated in abstract | animal | Research PMID 39827923 |
| Intraperitoneal | 15 mg/kg twice daily | Not explicitly stated; treatment concurrent with tumor inoculation period | animal | Research PMID 42266945 |
| Not stated in abstract | Not stated in abstract | During 10-day de-acclimatization period | animal | Research PMID 41654147 |
| Subcutaneous micro-osmotic pump | 0.1 μmol/24 h (continuous infusion) | 24 hours | animal | Research PMID 55 |
| Subcutaneous micro-osmotic pump | 0.1 μmol/24 h (continuous infusion) | 24 hours | animal | Research PMID 41811086 |
| Not stated in abstract | Not stated in abstract | Not stated in abstract | animal | Research PMID 41043625 |
| In vitro (cell culture) | 1.0 μM for 24 h OR 0.5 μM for 48 h | 24 h or 48 h | in_vitro | Research PMID 31081069 |
| In vitro (cell culture) | Not stated in abstract (cells treated at onset of differentiation) | Not stated in abstract | in_vitro | Research PMID 35842023 |
| In vitro (cell culture) | 10 μM (in vitro, BEAS-2B cells) | 2 h pretreatment | in_vitro | Research PMID 40472776 |
| In vitro (cell culture) | 50 μM (in vitro myotubes) | Not stated in abstract | in_vitro | Research PMID 42266945 |
| Ex vivo organ chamber | 2 μg/ml (ex vivo aortic ring preparation) | Not stated in abstract | animal | Research PMID 29242099 |
| Administration (route not stated); exercise study in humans (observational, no exogenous dosing) | Not stated in abstract | Not stated in abstract | animal | Research PMID 41520850 |
| subcutaneous injection | 5 mg | 3x per week · 4-8 weeks | biohackers and longevity-focused adults seeking metabolic optimization and insulin sensitivity improvements | [Community] |
| subcutaneous injection | 10 mg | 3x per week · 4-8 weeks | experienced biohackers and individuals with metabolic dysfunction or obesity | [Community] |
| subcutaneous injection | 5 mg | daily · 4 weeks | biohackers targeting anti-aging and longevity outcomes | [Community] |
| subcutaneous injection | 10 mg | daily · 4-6 weeks | advanced biohackers, individuals with significant metabolic disease markers | [Community] |
| subcutaneous injection | 5 mg | 5 days on, 2 days off · 8 weeks | biohackers interested in metabolic and longevity benefits with a cycling approach | [Community] |
| intramuscular injection | 5 mg | 3x per week · 4-8 weeks | biohackers preferring IM administration for potentially faster absorption | [Community] |
| subcutaneous injection | 2 mg | daily · 4 weeks | biohackers new to MOTS-c or those stacking with other mitochondrial peptides (e.g., Humanin, SS-31) | [Community] |
| subcutaneous injection | 10 mg | once per week · 8-12 weeks | longevity-focused biohackers on a maintenance or cost-conscious protocol | [Community] |
Blends containing this peptide
All studies (50)
- PMID 34728329 Human observational
Skeletal muscle fiber composition and genetic variation (K14Q polymorphism) - PMID 36303331 Human observational
Neurodegenerative diseases and ischemic stroke - PMID 40005438 Human observational
Sarcopenia in peritoneal dialysis patients - PMID 25738459 Mixed
Metabolic homeostasis, insulin resistance, and obesity - PMID 29242099 Mixed
Cardiovascular disease (coronary artery disease, myocardial infarction, heart failure) - PMID 30725119 Mixed
Metabolic homeostasis, insulin resistance, and obesity - PMID 33473109 Mixed
Aging and physical performance / healthspan - PMID 34253808 Mixed
Metabolic homeostasis, insulin resistance, and obesity - PMID 35842023 Mixed
Skeletal muscle homeostasis, performance, and cachexia - PMID 36066139 Mixed
Cardiovascular disease (coronary artery disease, myocardial infarction, heart failure) - PMID 36233287 Mixed
Aging and physical performance / healthspan - PMID 36629605 Mixed
Cardiovascular disease (coronary artery disease, myocardial infarction, heart failure) - PMID 36761202 Mixed
Aging and physical performance / healthspan - PMID 36824008 Mixed
Type 2 diabetes mellitus and diabetic complications - PMID 37290680 Mixed
Lung injury and respiratory diseases - PMID 37788894 Mixed
Antiviral activity (hepatitis B virus infection) - PMID 37834399 Mixed
Skeletal muscle homeostasis, performance, and cachexia - PMID 38716540 Mixed
Cancer (ovarian cancer, hepatocellular carcinoma, bone cancer pain, adrenal tumors) - PMID 39201408 Mixed
Cancer (ovarian cancer, hepatocellular carcinoma, bone cancer pain, adrenal tumors) - PMID 39321430 Mixed
Cancer (ovarian cancer, hepatocellular carcinoma, bone cancer pain, adrenal tumors) - PMID 39581216 Mixed
Cancer (ovarian cancer, hepatocellular carcinoma, bone cancer pain, adrenal tumors) - PMID 39706498 Mixed
Skeletal muscle homeostasis, performance, and cachexia - PMID 39827923 Mixed
Lung injury and respiratory diseases - PMID 40035775 Mixed
Lung injury and respiratory diseases - PMID 40403491 Mixed
Lung injury and respiratory diseases - PMID 40472776 Mixed
Lung injury and respiratory diseases - PMID 41004666 Mixed
Metabolic homeostasis, insulin resistance, and obesity - PMID 41083123 Mixed
Type 2 diabetes mellitus and diabetic complications - PMID 41520850 Mixed
Skeletal muscle homeostasis, performance, and cachexia - PMID 41654147 Mixed
Cardiovascular disease (coronary artery disease, myocardial infarction, heart failure) - PMID 41802484 Mixed
Lung injury and respiratory diseases - PMID 42142418 Mixed
Lung injury and respiratory diseases - PMID 42193373 Mixed
Cardiovascular disease (coronary artery disease, myocardial infarction, heart failure) - PMID 42243958 Mixed
Lung injury and respiratory diseases - PMID 42266945 Mixed
Skeletal muscle homeostasis, performance, and cachexia - PMID 42611943 Mixed
Host defense / antibacterial activity - PMID 55
0.1 μmol/24 h (continuous infusion) Subcutaneous micro-osmotic pump (animal) - PMID 29983246
- PMID 31081069 In vitro only
Osteoporosis and bone metabolism - PMID 33639272 In vitro only
Mesenchymal stem cell aging (in vitro) - PMID 34320351 Animal studies only
Type 1 diabetes / autoimmune pancreatic islet protection - PMID 37307934 Animal studies only
Pulmonary fibrosis - PMID 38206815 Animal studies only
Non-alcoholic steatohepatitis (NASH) and liver injury - PMID 39267782
- PMID 40425777
- PMID 41043625 Animal studies only
Osteoarthritis and cartilage protection - PMID 41268602 Animal studies only
Intrauterine growth restriction (IUGR) / placental protection - PMID 41764620 Animal studies only
Non-alcoholic steatohepatitis (NASH) and liver injury - PMID 41811086
0.1 μmol/24 h (continuous infusion) Subcutaneous micro-osmotic pump (animal) - PMID 42153537 Animal studies only
Ischemic flap / soft tissue transplantation survival